Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Trillium Therapeutics Inc (TRIL.TO)

Trillium Therapeutics Inc (TRIL.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 2,426,437
  • Shares Outstanding, K 104,995
  • Annual Sales, $ 148 K
  • Annual Income, $ -59,346 K
  • 60-Month Beta 1.40
  • Price/Sales 44,312.87
  • Price/Cash Flow N/A
  • Price/Book 8.52
Trade TRIL.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.51
  • Most Recent Earnings -0.18 on 11/12/21
  • Next Earnings Date 11/15/21
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Options Overview Details

View History
  • Implied Volatility 0.00%
  • Historical Volatility 13.05%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 170.21% on 03/12/21
  • IV Low 0.00% on 12/02/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 2
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 0
  • Open Int (30-Day) 0

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.23
  • Number of Estimates 1
  • High Estimate -0.23
  • Low Estimate -0.23
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +28.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.73 +7.36%
on 10/20/21
24.41 -4.42%
on 11/17/21
+1.47 (+6.72%)
since 10/19/21
3-Month
7.48 +211.90%
on 08/20/21
24.41 -4.42%
on 11/17/21
+15.82 (+210.65%)
since 08/19/21
52-Week
7.48 +211.90%
on 08/20/21
27.12 -13.97%
on 11/30/20
+0.38 (+1.66%)
since 11/19/20

Most Recent Stories

More News
Trillium: Q3 Earnings Snapshot

MISSISSAUGA, Ontario (AP) _ Trillium Therapeutics Inc. (TRIL) on Friday reported a loss of $19.3 million in its third quarter.

TRIL.TO : 23.33 (+0.47%)
Trillium Therapeutics Receives Final Court Order Approving Arrangement

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage...

TRIL : 18.44 (+2.62%)
TRIL.TO : 23.33 (+0.47%)
PFE : 53.04 (-3.00%)
Trillium Securityholders Approve Acquisition by Pfizer

CAMBRIDGE, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage...

TRIL : 18.44 (+2.62%)
TRIL.TO : 23.33 (+0.47%)
PFE : 53.04 (-3.00%)
Two Trillion-Dollar Industries Being Transformed By Tech

Big money is pouring into two disruptive segments in two of the world’s biggest industries - ...

BEP : 34.98 (-2.02%)
PLUG : 36.42 (-0.79%)
TRUE.CN : 1.070 (-11.57%)
DXD : 8.97 (-3.65%)
TRIL.TO : 23.33 (+0.47%)
PBH.TO : 124.92 (+0.56%)
ONC.TO : 2.11 (+3.94%)
CRH.TO : 4.99 (+0.40%)
A.I. Breakthrough Could Disrupt the $11 Trillion Medical Sector

A massive disruption now appears imminent in one of the world’s largest – and most important ...

TRUE.CN : 1.070 (-11.57%)
TREIF : 0.8453 (-11.02%)
TRIL.TO : 23.33 (+0.47%)
ONC.TO : 2.11 (+3.94%)
HEXO.TO : 1.29 (+0.78%)
FTRP.CN : 5.550 (+1.46%)
Most actively traded companies on the Toronto Stock Exchange

TORONTO — Some of the most active companies traded Monday on the Toronto Stock Exchange:

SU.TO : 30.93 (+1.28%)
ENB.TO : 47.87 (+0.74%)
MFC.TO : 23.40 (+1.43%)
HEXO.TO : 1.29 (+0.78%)
GWO.TO : 37.12 (+0.71%)
FTS.TO : 56.04 (+1.06%)
TRIL.TO : 23.33 (+0.47%)
RSI.TO : 5.88 (+0.86%)
Pfizer signs deal to buy Trillium Therapeutics for US$2.26 billion

TORONTO — Trillium Therapeutics Inc. has signed a deal to be bought by Pfizer Inc. in an agreement valued at US$2.26 billion.

TRIL.TO : 23.33 (+0.47%)
Pfizer to Acquire Trillium Therapeutics Inc.

Pfizer Inc. (NYSE: PFE) and Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical...

TRIL : 18.44 (+2.62%)
TRIL.TO : 23.33 (+0.47%)
PFE : 53.04 (-3.00%)
Pfizer to Acquire Trillium Therapeutics Inc.

Proposed acquisition strengthens Pfizer’s category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies

TRIL : 18.44 (+2.62%)
TRIL.TO : 23.33 (+0.47%)
PFE : 53.04 (-3.00%)
Trillium Therapeutics Reports Second Quarter 2021 Operating and Financial Results

CAMBRIDGE, Mass., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...

TRIL : 18.44 (+2.62%)
TRIL.TO : 23.33 (+0.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 23.68
2nd Resistance Point 23.56
1st Resistance Point 23.45
Last Price 23.33
1st Support Level 23.22
2nd Support Level 23.10
3rd Support Level 22.99

See More

52-Week High 27.12
Last Price 23.33
Fibonacci 61.8% 19.62
Fibonacci 50% 17.30
Fibonacci 38.2% 14.98
52-Week Low 7.48

See More

Business Summary

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar